Michael Baldwin

Dr. Michael Baldwin

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LELisa M. Eubanks
Lisa M. Eubanks
MHMark S. Hixon
Mark S. Hixon
WJWei Jin
Wei Jin
SHSukwon Hong
Sukwon Hong
CCColin M. Clancy
Colin M. Clancy
KJKim D Janda
Kim D Janda
Among the agents classified as “Category A” by the U.S. Centers for Disease Control and Prevention, botulinum neurotoxin (BoNT) is the most toxic protein known, with microgram quantities of the protein causing severe morbidity and mortality by oral or i.v. routes. Given that this toxin easily could be used in a potential bioterrorist attack, countermeasures urgently are needed to counteract the pathophysiology of BoNT. At a molecular level, BoNT exerts its paralytic effects through intracellular cleavage of vesicle docking proteins and subsequent organism-wide autonomic dysfunction. In an effort to identify small molecules that would disrupt the interaction between the light-chain metalloprotease of BoNT serotype A and its cognate substrate, a multifaceted screening effort was undertaken. Through the combination of in vitro screening against an optimized variant of the light chain involving kinetic analysis, cellular protection assays, and in vivo mouse toxicity assays, molecules that prevent BoNT/A-induced intracellular substrate cleavage and extend the time to death of animals challenged with lethal toxin doses were identified. Significantly, the two most efficacious compounds in vivo showed less effective activity in cellular assays intended to mimic BoNT exposure; indeed, one of these compounds was cytotoxic at concentrations three orders of magnitude below its effective dose in animals. These two lead compounds have surprisingly simple molecular structures and are readily amenable to optimization efforts for improvements in their biological activity. The findings validate the use of high-throughput screening protocols to define previously unrecognized chemical scaffolds for the development of therapeutic agents to treat BoNT exposure.

1 September 2004 in Protein Expression and Purification
Verified
Journal Article
Closed access
MBMichael Baldwin
Michael Baldwin
MBMarite Bradshaw
Marite Bradshaw
EJEric A Johnson
Eric A Johnson
JBJoseph T Barbieri
Joseph T Barbieri

1 September 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
AMAnthony W. Maresso
Anthony W. Maresso
MBMichael Baldwin
Michael Baldwin
Joseph BarbieriJoseph Barbieri
Joseph Barbieri
Pseudomonas aeruginosa ExoS is a bifunctional type III-secreted cytotoxin. The N terminus (amino acids 96–233) encodes a GTPase-activating protein activity, whereas the C terminus (amino acids 234–453) encodes a factor-activating ExoS-dependent ADP-ribosyltransferase activity. The GTPase-activating protein activity inactivates the Rho GTPases Rho, Rac, and Cdc42 in cultured cells and in vitro, whereas the ADP-ribosylation by ExoS is poly-substrate-specific and includes Ras as an early target for ADP-ribosylation. Infection of HeLa cells with P. aeruginosa producing a GTPase-activating protein-deficient form of ExoS rounded cells, indicating the ADP-ribosyltransferase domain alone is sufficient to elicit cytoskeletal changes. Examination of substrates modified by type III-delivered ExoS identified a 70-kDa protein as an early and predominant target for ADP-ribosylation. Matrix-assisted laser desorption ionization mass spectroscopy identified this protein as moesin, a member of the ezrin/radixin/moesin (ERM) family of proteins. ExoS ADP-ribosylated recombinant moesin at a linear velocity that was 5-fold faster and with a Km that was 2 orders of magnitude lower than Ras. Moesin homologs ezrin and radixin were also ADP-ribosylated, indicating the ERMs collectively represent high affinity targets of ExoS. Type III delivered ExoS ADP-ribosylated moesin and ezrin (and/or radixin) in cultured HeLa cells. The ERM proteins contribute to cytoskeleton dynamics, and the ability of ExoS to ADP-ribosylate the ERM proteins links ADP-ribosylation with the cytoskeletal changes associated with ExoS intoxication.

1 January 2010
Verified
Book Chapter
Closed access
PDF file
JHJames S. Henkel
James S. Henkel
MBMichael Baldwin
Michael Baldwin
Joseph BarbieriJoseph Barbieri
Joseph Barbieri

27 June 2006 in Biochemistry
Verified
Journal Article
Closed access
ZFZhuji Fu
Zhuji Fu
SCSheng Chen
Sheng Chen
MBMichael Baldwin
Michael Baldwin
GBGrant E. Boldt
Grant E. Boldt
ACAdam Crawford
Adam Crawford
JKJung-Ja P. Kim
Jung-Ja P. Kim

1 October 2005 in Infection and Immunity
Verified
Journal Article
Open access
PDF file
MBMichael Baldwin
Michael Baldwin
WTWilliam H. Tepp
William H. Tepp
CPChristina L. Pier
Christina L. Pier
MBMarite Bradshaw
Marite Bradshaw
MHMengfei Ho
Mengfei Ho
JBJoseph T. Barbieri
Joseph T. Barbieri
Clostridium botulinum neurotoxins (BoNTs) are the most toxic proteins for humans. The current clostridial-derived vaccines against BoNT intoxication have limitations including production and accessibility. Conditions were established to express the soluble receptor binding domain (heavy-chain receptor [HCR]) of BoNT serotypes A and E in Escherichia coli . Sera isolated from mice and rabbits immunized with recombinant HCR/A1 (rHCR/A1) from the classical type A-Hall strain (ATCC 3502) (BoNT/A1) and rHCR/E from BoNT serotype E Beluga (BoNT/E B ) neutralized the homologous serotype of BoNT but displayed differences in cross-recognition and cross-protection. Enzyme-linked immunosorbent assay and Western blotting showed that α-rHCR/A1 recognized epitopes within the C terminus of the HCR/A and HCR/E, while α-rHCR/E recognized epitopes within the N terminus or interface between the N and C termini of the HCR proteins. α-rHCR/E B sera possessed detectable neutralizing capacity for BoNT/A1, while α-rHCR/A1 did not neutralize BoNT/E. rHCR/A was an effective immunogen against BoNT/A1 and the Kyoto F infant strain (BoNT/A2), but not BoNT serotype E Alaska (BoNT/E A ), while rHCR/E B neutralized BoNT/E A , and under hyperimmunization conditions protected against BoNT/A1 and BoNT/A2. The protection elicited by rHCR/A1 to BoNT/A1 and BoNT/A2 and by rHCR/E B to BoNT/E A indicate that immunization with receptor binding domains elicit protection within sub-serotypes of BoNT. The protection elicited by hyperimmunization with rHCR/E against BoNT/A suggests the presence of common neutralizing epitopes between the serotypes E and A. These results show that a receptor binding domain subunit vaccine protects against serotype variants of BoNTs.